$14.08
Value $5.5B
LFST and MRK stock compared: price, dividend, valuation and results, from SEC filings.
$14.08
Value $5.5B
$147.76
Value $365B
LifeStance Health (LFST) has a market value of $5.5B and Merck & Company (MRK) $365B. Over the last year, with dividends, LFST moved +118.6% and MRK +66.3%. The P/E is 76.3 for LFST and 148.9 for MRK. Dividend yield: LFST none, MRK 2.30%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
LFST$5.5B
MRK$365B
MRK is 67 times LFST
Revenue, 12 months
LFST$1.7B
MRK$67.4B
MRK is 40 times LFST
Net income, 12 months
LFST$72M
MRK$2.5B
MRK is 34 times LFST
Operating margin
LFST6.2%
MRK–
ROIC
LFST4.7%
MRK3.9%
0.8 points apart
P/E
LFST76.3
MRK148.9
MRK is 2.0 times LFST
Dividend yield
LFST0.0%
MRK2.3%
2.3 points apart
5-year return
LFST+36.2%
MRK+104.9%
68.7 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
LFST+36.2%
MRK+104.9%
| Period | LFSTWith dividends | MRKWith dividends |
|---|---|---|
| 1 year since November 12, 2025 | +118.6%Price +118.6% | +66.3%Price +61.6% |
| 3 years since November 13, 2023 | +149.2%+35.6% a yearPrice +149.2% | +58.0%+16.5% a yearPrice +44.2% |
| 5 years since November 12, 2021 | +36.2%+6.4% a yearPrice +36.2% | +104.9%+15.4% a yearPrice +75.9% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
LFSTLifeStance HealthMRKMerck & Company
| Price | $14.08 | $147.76 |
|---|---|---|
| Market value | $5.5B | $365B |
| Enterprise value (EV) | $5.5B | $409B |
| P/E | 76.3 | 148.9 |
| P/E, 5-year median | – | 14.8 |
| P/B | 3.7 | 8.1 |
| EV/EBIT | 53.2 | 86.0 |
| Free cash flow yield | 3.3% | 4.0% |
| Revenue, 12 months | $1.7B | $67.4B |
|---|---|---|
| Net income, 12 months | $72M | $2.5B |
| Free cash flow, 12 months | $179M | $14.7B |
| Earnings per share, 12 months | $0.18 | $0.98 |
| Revenue growth, year on year | 13.9% | 1.3% |
| Revenue growth a year, past | +20.9%over 4 years | +9.4%over 5 years |
| EPS growth a year, past | – | +21.2%over 5 years |
| Gross margin | – | 71.8% |
|---|---|---|
| Operating margin | 6.2% | – |
| Net margin | 4.3% | 3.6% |
| ROIC | 4.7% | 3.9% |
| ROE | 4.8% | 5.2% |
| Cash | $219M | $9.7B |
|---|---|---|
| Total debt | $476M | $53.8B |
| Net debt / EBITDA | 0.4 | 5.7 |
| Interest cover | 10.6× | 2.4× |
| Dividend yield | – | 2.3% |
|---|---|---|
| Dividend per share, 12 months | – | $3.40 |
| Dividend growth a year, past | – | +5.8%over 5 years |
| Buyback yield | – | 1.4% |
| Shareholder yield | – | 3.7% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Merck & Company ($365B) is about 66.6 times LifeStance Health ($5.5B), at today's prices.
Since November 12, 2021, LFST's price moved +36.2% and MRK's +75.9%. With dividends: LFST +36.2% (+6.4% a year), MRK +104.9% (+15.4% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for LifeStance Health and 2.30% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.
At today's price, the P/E is 76.3 for LFST and 148.9 for MRK. It is the share price over the last twelve months' earnings per share.
Over the last twelve months, the net margin was 4.3% for LifeStance Health and 3.6% for Merck & Company, and the operating margin 6.2% and –. Revenue was $1.7B and $67.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.